E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Great Debates and Updates in GI Malignancies


Register Now

Great Debates and Updates in GI Malignancies

March 25-26, 2011

New York, New York

 

ACCME

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this live educational activity for a maximum 14.0 of AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Who Should Attend/Target Audience
This educational activity is intended for medical oncologists, gastroenterologists, pathologists, radiologists, and other physicians and healthcare professionals in active clinical practice who are interested and/or involved in the care of patients with GI cancers.

Learning Objectives
After successful completion of this continuing medical education activity, attendees should be able to:

  • Discuss the significance and utilization of at least one prognostic or predictive biomarker in colorectal and gastric cancers
  • Assign a therapy based upon biomarker test analysis
  • Discuss the current and future role of biologic and targeted therapies in managing GI cancers
  • Recommend the most appropriate adjuvant or neoadjuvant therapy regimen for patients with GI cancer
  • Summarize the role of radiotherapy in GI malignancies
  • Comment on available treatment options for GIST, biliary tract cancer, neuroendocrine tumors, carcinoid tumors, and peritoneal carcinomatosis
  • Recommend the most optimal therapeutic algorithm based upon current and emerging data

Ghassan K. Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center
Weill Medical College at Cornell University
New York, New York

Steven R. Alberts, MD, MPH
Mayo Clinic
Rochester, Minnesota

David L. Bartlett, MD
University of Pittsburgh Medical Center Cancer Pavilion
Pittsburgh, Pennsylvania

Jordan D. Berlin, MD
Vanderbilt University
Nashville, Tennesse

James M. Epstein, MD
Imedex, LLC
Alpharetta, Georgia

Axel Grothey, MD
Mayo Clinic
Rochester, Minnesota

Michael G. Haddock, MD
Mayo Clinic
Rochester, Minnesota

Daniel G. Haller, MD
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania

Howard S. Hochster, MD
Yale Cancer Center
New Haven, Connecticut

David H. Ilson, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

John L. Marshall, MD
Georgetown University
Washington, DC

Wells A. Messersmith, MD, FACP
University of Colorado Cancer Center
Aurora, Colorado

Michael A. Morse, MD, MHS
Duke University Medical Center
Durham, North Carolina

Eileen M. O'Reilly, MD
Memorial Sloan-Kettering Cancer Center
Weill Medical College of Cornell University
New York, New York

Susan G. Urba, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan

James C. Yao, MD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Friday, March 25, 2011

Session I: Colorectal cancer I
Chair: Axel Grothey, MD

8:00 am
Welcome and introduction
Axel Grothey, MD and Daniel G. Haller, MD

8:05 am
Pre-session survey via ARS

8:15 am
Debate: What is the most appropriate adjuvant therapy for a fit 78 year old with resected stage III colon cancer?

mFOLFOX6 or XELOX
Daniel G. Haller, MD

5-FU/LV or capecitabine alone
Howard S. Hochster, MD

8:45 am
Debate: Can CRC biomarker results help guide monitoring schedules for patients completing adjuvant therapy?

Yes, patients whose results suggest higher risk should be monitored more closely
Daniel G. Haller, MD

No, all patients should be monitored on the same schedule
Michael A. Morse, MD, MHS

9:15 am
Why did cetuximab fail to improve DFS in the phase III N0147 trial for resected stage III colon cancer patients, and what should we be doing differently in CRC adjuvant trials?

From the inside looking out
Steven R. Alberts, MD, MPH

From the outside looking in
John L. Marshall, M

9:55 am
Debate: Can dMMR and Oncotype DX for CRC select patients with stage II CRC most likely benefit from systemic adjuvant therapy

Yes
Axel Grothey, MD

No
Michael A. Morse, MD, MHS

10:25 am
Coffee break

Session II: Pancreatic cancer I
Chair: Daniel G. Haller, MD

10:45 am
Pancreatic neuroendocrine tumors – How frequent, how serious, how treatable?
James C. Yao, MD

11:15 am
Debate: What is the standard of care for a 55 year old man with advanced pancreatic cancer and an ECOG performance status of 1?

Gemcitabine +/- erlotinib
Eileen O’Reilly, MD

FOLFIRINOX
David H. Ilson, MD, PhD

11:45 am
Is there any progress in the development of new agents for pancreatic adenocarcinoma?
Jordan D. Berlin, MD

12:15 pm
Post session survey via ARS

12:25 pm
Lunch with the faculty

Session III: How I manage I
Chair: James Epstein, MD

1:30 pm
Carcinoid tumors
James C. Yao, MD

1:55 pm
Biliary tract cancers
Ghassan K. Abou-Alfa, MD

2:20 pm
PET scanning in the management of my GI cancer patients
Howard S. Hochster, MD

2:45 pm
Coffee Break

Session IV: Case discussions

3:00 pm
Colorectal cancer case discussion
Moderator: Axel Grothey, MD
Panel: Daniel G. Haller, MD,
John L. Marshall, MD, and
Wells A. Messersmith, MD, FACP

3:45 pm
Upper GI cancers case discussion
Moderator: David H. Ilson, MD, PhD
Panel: Steven R. Alberts, MD, MPH, and
Susan G. Urba, MD

4:20 pm
Post session survey via ARS

4:30 pm
Adjourn

Saturday, March 26, 2011

Session V: Colorectal cancer II

8:00 am
Welcome back
Axel Grothey, MD and
Daniel G. Haller, MD

8:05 am
Pre session survey via ARS

8:15 am
Debate: What is the best frontline management strategy for T3N0 adenocarcinoma of the mid-rectum?

Neoadjuvant combination chemotherapy alone
Howard S. Hochster, MD

Flourouracil-based chemoradiation
Michael G. Haddock, MD

8:45 am
Combining chemotherapy with biologic agents in colorectal cancer – positives, negatives, sequences versus combinations and the questions still unanswered
Axel Grothey, MD

9:15 am
Debate: Is there a role for maintenance therapy in the management of advanced colorectal cancer patients responding to frontline systemic therapy?

Yes
Speaker invited

No
Wells A. Messersmith, MD, FACP

9:45 am
Debate: What is the optimal management for stage IV colon cancer patients presenting with unresectable metastatic disease and an asymptomatic primary tumor?

Surgical resection of the primary cancer followed by chemotherapy +/- a biologic agent
Michael A. Morse, MD, MHS

Systemic therapy with chemotherapy +/- a biologic agent followed by resection of the primary cancer
Wells A. Messersmith, MD, FACP

10:15 am
Coffee break

Session VI: Gastroesophageal cancers
Chair: Axel Grothey, MD

10:45 am
Debate: Has the AVAGAST trial resolved the question regarding the role and value of bevacizumab in advanced gastric cancer?

Yes, it was definitively negative
Jordan D. Berlin, MD

No, there is still an opening for bevacizumab
Susan G. Urba, MD

11:15 am
Debate: What is the best neoadjuvant approach for locally advanced gastroesophageal junction HER2-negative adenocarcinoma?

Chemotherapy followed by resection followed by adjuvant chemotherapy
Speaker invited

Chemotherapy followed by resection followed by chemoradiation
Michael G. Haddock, MD

11:45 am
Debate: What is the optimal multimodality therapy for locally advanced squamous cell carcinoma of the esophagus?

5-FU-cisplatin-radiation
David H. Ilson, MD, PhD

Carboplatin-paclitaxel-radiation
Susan G. Urba, MD

12:15 pm
Post session survey via ARS

12:20 pm
Lunch with faculty

Session VII: How I manage II
Chair: James Epstein, MD

1:20 pm
Peritoneal carcinomatosis
David L. Bartlett, MD

1:45 pm
Hepatocellular carcinoma
Ghassan K. Abou-Alfa, MD

2:10 pm
Coffee break

Session VIII: Pancreatic cancer II
Chair: Daniel G. Haller, MD

2:30 pm
What is the best therapeutic approach to locally advanced pancreatic cancer?

Chemotherapy followed by chemoradiation
Eileen O’Reilly, MD

Chemotherapy alone
Jordan D. Berlin, MD

3:00 pm
What is the best adjuvant therapy for resected adenocarcinoma of the pancreas?

Gemcitabine +/- erlotinib
John L. Marshall, MD

Gemcitabine +/- erlotinib followed by fl ouropyrimidine-radiation
Eileen O’Reilly, MD

5-FU alone
Steven R. Alberts, MD

3:45 pm
Post session survey via ARS

4:00 pm
Adjourn

 

Information coming soon.

Discounted
Payment received by January 28, 2011

$150.00

Regular
Payment received by March 17, 2011

$200.00

Full/Onsite
If payment received after March 17, 2011

$250.00

Nurses/Residents/Students*
*Proof of eligibility must accompany registration; cannot be combined with any other discounts.

$99.00

To Register: You may register online March 17, 2011 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later March 17, 2011. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full.

Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance continuing medical education, and all event functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than March 17, 2011. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after March 17, 2011.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

New York Marriott Downtown
85 West Street at Albany
New York, New York 10006
Tel.: +1 (212) 385 4900
Fax: +1 (212) 227 8136
www.nymarriottdowntown.com

For the convenience of attendees, a room block with a limited number of rooms has been reserved at the discounted group rate of $ 179.00 single/double occupancy, plus tax, currently at 14.75% plus a $3.50 occupancy tax. This limited number of discounted rooms will be available until March 3, 2011. This discounted rate is not guaranteed outside the conference dates. Reservations received after March 3, 2011 or after the room block has been filled (whichever comes first) are subject to availability and prevailing hotel rates.

To reserve your room please contact the New York Marriott Downtown reservations department at +1 (212) 385 4900 or visit the hotel’s website at www.nymarriottdowntown.com. To receive the group rate, callers must identify themselves as being with the Imedex/Great Debates and Updates in GI Malignancies group. Reservation requests received after March 3, 2011 may not be guaranteed the group rate.

The Registration and Information Desk at the New York Marriott Downtown will be staffed:

Friday, March 25, 2011
7:00 am – 4:30 pm

Saturday, March 26, 2011
7:00 am – 4:30 pm

Letter from the Chairs:

Dear Colleague,

We invite you to join us in New York City this March for Great Debates and Updates in GI Malignancies.

This meeting is a different kind of educational event – one we know you will enjoy and learn from. Recognized thought leaders engage in lively and interactive debates over some of the most controversial topics in the field and offer selected didactic presentations on the latest developments in colorectal cancer, GIST, pancreatic cancer, upper GI malignancies and more. Faculty and audience discussion is encouraged with a focus on how new information fits into current community practice in the field, providing you with the opportunity to learn how experts in the field manage their patients. New debates and topics this year will offer valuable information for repeat attendees as well as those new to the meeting.

The unique and instructive format of Great Debates and Updates in GI Malignancies will keep you up to date in the field and give you expert insight into the management of your GI patients. We hope to see you there!

Sincerely,

Axel Grothey, MD
Daniel G. Haller, MD

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Chairs

Axel Grothey, MD
Mayo Clinic
Rochester, Minnesota

Daniel G. Haller, MD
Abramson Cancer Center
at the University of Pennsylvania
Philadelphia, Pennsylvania

Moderator

James Epstein, MD
Senior Medical
Advisor Imedex, LLC
Alpharetta, Georgia

Quotes from Past Participants

Amazing cutting-edge discussion

Debates were very stimulating; Impressed with how serious the speakers took their side of the debate

Excellent review of data on both sides of difficult questions

Really excellent-vote/debate format increased understanding and recall

Enjoyed the interaction among the faculty following the presentations

Very well done conference with quality faculty

The following companies have provided an educational grant in support of this conference:

PLATINUM

Genentech

 

GOLD

Lilly

 

CORPORATE

Genomic Health

 

Several options are available to companies interested in supporting this conference.
For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.

Information coming soon.

Opportunities are available to companies interested in exhibiting at this conference.
For more information, please contact Cori Gunter at +1 (678) 242 0712, or by email at c.gunter@imedex.com.